ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact

Caris Life Sciences and ESSA Pharma Inc EPIX have announced a Precision Development program to support ESSA's development of EPI-7386 in metastatic castration-resistant prostate cancer (mCRPC) failing current standard-of-care therapies.
Under the terms of the agreement, Caris and ESSA will evaluate patient blood samples to assess genetic profiles utilizing Caris' Whole Transcriptome Sequencing and Whole Exome Sequencing platform.
ESSA will utilize these liquid biopsies, including longitudinal data from serial samples, to better characterize the tumor biological profiles of patients in the ongoing monotherapy clinical trial of EPI-7386 in mCRPC patients.
The information may facilitate more efficient development of EPI-7386 by identifying relevant patient tumor biological subpopulations, the Company said.
Price Action: EPIX stock is down 1.13% at $7.86 during the market session on the last check Thursday.